Key statistics
As of last trade, Poseida Therapeutics Inc (2RZ:BER) traded at 2.68, 45.51% above the 52 week low of 1.84 set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.59 |
---|---|
High | 2.68 |
Low | 2.58 |
Bid | 2.58 |
Offer | 2.81 |
Previous close | 2.59 |
Average volume | 872.00 |
---|---|
Shares outstanding | 97.47m |
Free float | 70.52m |
P/E (TTM) | -- |
Market cap | 264.13m USD |
EPS (TTM) | -0.635 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:58 GMT.
More ▼
Press releases
- Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
- Poseida Therapeutics to Present at Two Upcoming Investor Conferences
- Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
- Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
- Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
- Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
- Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
- Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
- Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
- Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
More ▼